bluuebunny/crossref_metadata_2025_split huggingface dataset:
IV‐S neuroblastoma: A cooperative study of 30 children
Authors: Mancini Antonia F. , Rosito Pasquale , Vitelli Arnaldo , Paolucci Paolo , Vecchi Vico , Paolucci Guido , de Bernardi Bruno , Calculli Giovanni , Carli Modesto , Castello Manuel , Marchi Antonietta , Massolo Fausta , Mastrangelo Renato , Pastore Guido , Pianca Clotilde , Zanazzo Giulio Andrea 
Published: February 2007

AbstractThe clinical features of 30 children with IVS neuroblastoma have been reviewed. They were treated at 11 Italian pediatric institutions in the period 1970‐1981. Patients with IV‐S neuroblastoma comprise 6.1% of all the neuroblastoma cases observed during that period. The age at diagnosis ranged from birth to 11 months (mean, 3 months). The distribution of “primary” lesions was of interest. The adrenal gland was affected most often (57% of patients), but tumors of the chest and neck were also encountered. No specific “primary” lesion was identified in ten children. The most frequent site of widespread disease was the liver (87%). Neither the size of the “primary” tumor, nor the number or size of subcutaneous nodules was of prognostic significance. Unfavorable features were age less than 2 months and clinical signs of pulmonary, renal, or hepatic embarrassment. These data confirm the need for prompt intervention in the infant who is suffering from compression of these vital structures by the enlarged liver. Radiation therapy is to be preferred for this purpose, because of the often severe toxicity that is associated with chemotherapy in infants. One, and possibly two babies in this series died of chemotherapy‐related complications.
Peptichemio in neuroblastoma at relapse
Authors: Pastore G. , de Bernardi B. , Carli M. , Acquaviva A. , Cordero Montezemolo L. Di , Loiacono G. , Tamaro P. 
Published: February 2007

AbstractPeptichemio (PTC), a multipeptidic complex of m‐L‐phenyl‐alanine mustard, was administered to 39 children with neuroblastoma at relapse. The compound was given in two 5‐day cycles at dosages varying from 1.0‐1.5 mg/kg/day. We were able to evaluate 29 of the initial 39 children for PTC effect; 21 of them had received PTC as first therapy following diagnosis. Ten patients underwent other chemotherapy for relapse before PTC. Three patients were off therapy when relapse occurred.Subjective improvement was observed in 18 cases (62%). Eleven patients (38%) experienced an objective regression, which was scored as complete response in three cases, partial response in two, mixed response in six. In ten children no significant disease change was observed; the remaining eight had a progression of their disease while receiving PTC. The incidence of responses has been higher in patients off therapy at moment of relapse, and lower in those pretreated for their relapse. Previous administration of PTC did not reduce the chance of response at relapse.Major toxic effects were transient, mostly moderate myelodepression and phleboscle‐rosis. Allergic reactions, nausea, and vomiting, occurred in a few patients.These data indicate that PTC may exert objective antitumor activity in approximately one‐third of neuroblastoma patients at relapse.
Anaphylactic reaction to cytarabine: In vitro evidence that the response is immunoglobulin e mediated
Authors: Markman Maurie , Howell Stephen B. , King Mark , Pfeifle Craig , Wasserman Stephen I. 
Published: February 2007

AbstractA 48‐year‐old female developed significant bronchospasm on two occasions after being treated with cytarabine (Ara‐C) by the intraperitoneal route. In this report we present the first in vitro evidence that such a reaction to cytarabine can be associated with the release of histamine and therefore might be immunoglobulin E (IgE) mediated. In addition, this report emphasizes the fact that, while uncommon, severe allergic reactions to this useful chemotherapeutic agent do occur and must be considered in the differential diagnosis of anaphylaxis and related symptoms in patients receiving this drug.
Treatment of advanced head and neck cancer: Multiple daily dose fractionated radiation therapy and sequential multimodal treatment approach
Authors: Nissenbaum Michael , Browde Selma , Bezwoda Werner R. , de Moor Norah G. , Derman Dennis P. 
Published: February 2007

AbstractFifty‐eight patients with advanced head and neck cancer were entered into a randomised trial comparing chemotherapy (DDP + bleomycin) alone, multiple daily fractionated radiation therapy, and multimodality therapy consisting of chemotherapy plus multiple fractionated radiation therapy. Multimodal therapy gave a significantly higher response rate (69%) than either single‐treatment modality. The use of a multiple daily dose fractionation allowed radiation therapy to be completed over 10 treatment days, and the addition of chemotherapy to the radiation treatment did not significantly increase toxicity. Patients receiving multimodal therapy also survived significantly longer (median 50 weeks) than those receiving single‐modality therapy (median 24 weeks).
Maturation of Wilms' tumor pulmonary metastases to benign fibromas after therapy
Authors: Silván A. M. Alvarez , Gonzalez del Castillo J. , Caro A. Martinez , Vallés M. C. Garcia , Cuevas G. Pineda , Arcega M. A. Maillo , Barrios A. López 
Published: February 2007

AbstractA 3‐year‐old girl with Wilms' tumor developed pulmonary metastases 5 months after diagnosis. All but one of the visible lesions disappeared after thoracic irradiation and multiple‐agent chemotherapy. Subsequent thoracotomy revealed 17 small nodules in addition to the visible lesion, and all of them proved to be fibromas. It would appear that the Wilms' tumor metastases to the lung were made to mature to benign neoplastic processes after the treatments given.
Ascending myelopathy after chemotherapy for central nervous system acute lymphoblastic leukemia: Correlation with cerebrospinal fluid myelin basic protein
Authors: Bates Susan E. , Raphaelson Marc I. , Price Robert A. , McKeever Paul , Cohen Steve , Poplack David G. 
Published: February 2007

AbstractAscending myelopathy developed in a previously irradiated 10‐year‐old boy after intra‐ventricular methotrexate and cytosine arabinoside were given for central nervous system relapse of acute lymphoblastic leukemia. The course was fatal in 10 weeks. Cerebrospinal fluid myelin basic protein levels, indicating a demyelinative process, rose prior to the onset of clinical symptoms and remained at very high levels until death. Myelin basic protein may be useful as a predictor of chemotherapy‐associated neurotoxicity.
Leydig cell damage after testicular irradiation for lymphoblastic leukaemia
Authors: Shalet S. M. , Horner Alison , Ahmed S. R. , Morris‐Jones P. H. 
Published: February 2007

AbstractThe effect of testicular irradiation on Leydig cell function has been studied in a group of boys irradiated between 1 and 5 years earlier for a testicular relapse of acute lymphoblastic leukaemia. Six of the seven boys irradiated during prepubertal life had an absent testosterone response to HCG stimulation. Two of the four boys irradiated during puberty had an appropriate basal testosterone level, but the testosterone response to HCG stimulation was subnormal in three of the four. Abnormalities in gonadotrophin secretion consistent with testicular damage were noted in nine of the 11 boys. Evidence of severe Leydig cell damage was present irrespective of whether the boys were studied within 1 year or between 3 and 5 years after irradiation, suggesting that recovery is unlikely. Androgen replacement therapy has been started in four boys and will be required by the majority of the remainder to undergo normal pubertal development.
Pneumococcal vaccination in children with acute lymphocytic leukemia
Authors: Feldman Sandor , Malone W. , Wilbur Richard , Schiffman Gerald 
Published: February 2007

AbstractSixty‐three children with ALL in CCR and treated according to a standard therapy protocol were immunized with the 14‐valent pneumococcal vaccine. Forty‐six children were vaccinated 1, 3, or 6 months following initial induction remission; 15 were vaccinated 4–6 weeks following successful completion of 30 months of antileukemia therapy; and two were vaccinated at the time of diagnosis. Response to the vaccine was suboptimal and by the 6‐month follow‐up there were only two serotypes for which more than half the patients tested had > 300 ng antibodies N/ml.
Graft‐versus‐host disease in rhabdomyosarcoma following transfusion with nonirradiated blood products
Authors: Labotka Richard J. , Radvany Ruta 
Published: February 2007

AbstractGraft‐versus‐host disease is a complication of transfusion of nonirradiated blood products into an immunocompromised patient, and it has been reported in hematologic and lymphoid malignancies as well as in neuroblastoma in children. We report the first case of acute graft‐versus‐host disease in a child undergoing chemotherapy for a rhabdomyosarcoma, who received transfusions during an intercurrent illness. The graft‐versus‐host disease was accompanied by an allogeneic lymphoid graft and was diagnosed on the basis of HLA studies on the patient's and her family's circulating lymphocytes and confirmed by HLA typing of the patient's skin fibroblasts.
Successful treatment of pulmonary and abdominal metastatic osteosarcoma
Authors: Takaue Yoichi , Slopis John M. , Anzai Takashi , Robertson Resa , Jaffe Norman 
Published: February 2007

AbstractA patient with telangiectatic osteosarcoma of the proximal fibula while receiving adjuvant chemotherapy, developed pulmonary and, later, mesenteric metastases. The pulmonary metastases were resected and the mesenteric metastasis was eradicated with surgery and intra‐arterial cis‐diamminedichloroplatinum II. This represents an additional example of an alteration in the clinical pattern of metastases induced by chemotherapy and the ability to achieve cure with a multidisciplinary approach.
Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft‐versus‐host disease
Authors: Sanders Jean E. , Flournoy Nancy , Thomas E. Donnall , Buckner C. Dean , Lum Lawrence G. , Clift Reginald A. , Appelbaum Frederick R. , Sullivan Keith M. , Stewart Patricia , Deeg H. Joachim , Doney Kristine , Storb Rainer 
Published: February 2007

AbstractOne hundred fourteen children with acute lymphoblastic leukemia were treated with allogeneic marrow transplantation from HLA‐identical siblings after conditioning with cy‐clophosphamide and total body irradiation. Methotrexate was given posttransplantation for prophylaxis of graft‐versus‐host disease. The minimum follow‐up after transplantation was 2 years. Sixteen of 51 patients transplanted in marrow remission survive from 2.1 to 8.9 years (median 2.7), 13 in continuous remission, one in remission following testicular relapse, and two after marrow relapse. Sixty‐three were transplanted in relapse and eight survived 3–10 years (median 5.7), five in continuous remission, and three in remission following testicular relapse. In a multivariate analysis, factors significantly related to increased survival were marrow remission at transplant (p < 0.007) and chronic graft‐versus‐host disease (p < 0.005). Factors associated with increased relapse were marrow relapse at transplant (p < 0.002) and absence of significant graft‐versus‐host disease (p < 0.004). The development of acute graft‐versus‐host disease was associated with high marrow cell doses (p < 0.04). These data suggest that some children with acute lymphoblastic leukemia and a poor prognosis with conventional chemotherapy may be cured with marrow transplantation.
Response of therapy‐associated acute nonlymphocytic leukemia to intensive induction chemotherapy
Authors: Duane Steven F. , Peterson Bruce A. , Bloomfield Clara D. , Michels Sheryl D. , Hurd David D. 
Published: February 2007

AbstractAmong 31 consecutive patients who developed acute nonlymphocytic leukemia following treatment with chemotherapy or radiation therapy, 17 were treated with intensive chemotherapy aimed at inducing a complete remission. Seven of these 17 patients (41%) obtained a complete remission that ranged in duration from 2 to 11 (median 3) months. Two additional patients who failed to develop normal peripheral blood counts despite postinduction bone marrows that were normocellular and free of leukemia were classified as nonresponders. The median time to complete remission and median duration of leukopenia (WBC < 1,000/μ1) were 34 days and 23 days, respectively. Induction chemotherapy was complicated by fever in all patients, documented infection in six patients, and death secondary to sepsis in three. Survival of the 17 patients ranged from <1 to 39 (median 4) months. Patients achieving a complete remission had a median survival time of 10 months compared to 2 months for the nonresponders. The other 14 patients received only supportive care and had a median survival of 2 months. These findings indicate that therapy‐associated acute nonlymphocytic leukemia (t‐ANLL) can frequently respond to chemotherapy and that achieving a complete remission is associated with longer survival. Although these results are encouraging, patients with t‐ANLL still have a relatively poor prognosis and efforts directed at improving treatment outcome need to be continued.
Sarcoma metastatic to the central nervous system parenchyma: A review of the literature
Authors: Sarno James B. , Wiener Leo , Waxman Marian , Kwee James 
Published: February 2007

AbstractSarcoma metastatic to cerebral parenchyma, although rare, occurs more frequently than generally recognized. With increased duration of survival due to multi‐modal therapy, more CNS metastases are being found. A literature search occasioned by a patient with metastatic sarcoma has produced some interesting results.
Neuropsychologic function in children with brain tumors: III. Interval changes in the six months following treatment
Authors: Mulhern Raymond K. , Kun Larry E. 
Published: February 2007

AbstractTwenty‐six children with primary brain tumors were studied prospectively with regard to their sensorimotor, intellectual, academic, and emotional status. Serial evaluations were conducted after surgery (pre‐irradiation) and six months after the completion of radiation therapy. The timing of the second evaluation was chosen so as to antedate the late effects of irradiation. Children over 6 years old displayed significant improvement of intellectual function over time, with only 11% exhibiting deterioration on one or more cognitive parameters. In contrast, 68% of younger children clinically deteriorated in one or more areas of intellectual functioning, with prominent difficulties in memory and selective attention for age. Children under 6 years old with supratentorial tumors were less likely than those with posterior fossa tumors to improve their cognitive performance. At the second evaluation, 23% of the patients were functioning below normal (IQ < 80) intellectually, with 50% of the younger children and 11% of the older children receiving special educational assistance. Approximately 40–50% of the patients manifested emotional adjustment problems at each evaluation. The results are discussed in terms of the clinical need to follow similar patient populations with formal psychological assessments over time, and in terms of the difficulties involved in defining factors that determine the functional status of children surviving brain tumors.
Secondary polycythaemia associated with large cell lymphoma
Authors: Abdi E. A. , Ding J. C. , Cooper I. A. 
Published: February 2007

AbstractWe describe the case of a 53‐year‐old woman in whom early stage large cell lymphoma appears to be associated with secondary erythrocytosis. A haemogram obtained six months earlier had been normal, but at the time lymphoma was diagnosed, investigations showed haemoglobin 20.5 gm/dl, total red cell count 6 1012/liter, haematocrit 0.60 liters/liter, whole blood volume 81.1 ml/kg, red cell volume 43.2 ml/kg, and plasma volume 37.8 ml/kg. Other investigations revealed no evidence of any other myeloproliferative disorder, and common causes of tissue hypoxia and other well‐known causes of secondary polycythaemia were excluded. Combination chemotherapy employed to treat lymphoma reverted the abnormal blood counts to normal. We believe this to be the first described case of an association of lymphoma and secondary polythaemia.
Steroid receptors in a granulosa cell tumor (GCT) in an infant with precocious puberty
Authors: Leiberman E. , Glezerman M. , Karny N. , Levy J. 
Published: February 2007

AbstractA granulosa theca cell tumor was found in a 10‐month‐old girl with precocious puberty. Steriod hormone receptors were measured in fractionated tumor cells. Estrogen and progesterone receptors were measured in the cytosol, and estrogen receptors were measured in the nuclear fraction of the tumor. Although high affinity (Kd 0.4 nM) progesterone receptors were present in the cytosol of this tumor—54 fmole/mg protein—no cytosolic estradiol receptors could be detected; however, these receptors were found to be tightly bound to the nuclear fraction of the tumor. The nuclear protein had lower apparent Kd for the hormones—5.4 nM. This tumor produced and released various steroid hormones. The plasma steroid levels before removal of the tumor were 1,200 pg/ml for estradiol, 350 pg/ml for testosterone, and 5 ng/ml for progesterone. All these steroid hormones declined postoperatively to undetectable levels, with total remission of pubertal signs. Plasma‐dehydroepiandrosterione, prolactin, and gonadotropin levels were in the normal range before and after surgery. These results suggest that cytosolic progesterone receptor as an estrogenic marker and/or nuclear estrogen receptors may predict the hormonal dependency of these estrogen‐producing tumors.
Sudden cerebral death in malignant presacral teratoma
Authors: Chan Ka Wah , Fryer Christopher J. H. , Fraser Graham C. , Dimmick James E. 
Published: February 2007

AbstractA three‐year‐old girl with disseminated malignant teratoma was treated by palliative radiotherapy to her pulmonary metastases. She developed seizure followed by absence of cerebral function and death ensued in 36 hours. Computerized scan of brain was negative prior to death. The main finding at autopsy was occlusion of the carotid and cerebral arteries by necrotic tumour. Widespread cerebral tumour embolization may be an unusual terminal event in cancer patients with pulmonary metastases.
Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4′epi‐adriamycin in combination with cisplatin and cyclophosphamide
Authors: Bezwoda W. R. 
Published: February 2007

AbstractFifty‐one patients with ovarian cancer were entered in a randomised trial comparing treatment with cisplatin + adriamycin + cyclophosphamide (PAC) to cisplatin + 4′epi‐adriamycin + cyclophosphamide (PEC). Complete response rates for the two treatment arms were similar (9/27 PAC, 14/24 PEC). Patients with < 2 cm residual disease had significantly higher rate of complete remission than those with > 2 cm residual disease. Cardiotoxicity was significantly less in the PEC‐treated group (0/24) as compared with the PAC‐treated group (6/27, χ2 = 4.09, p < 0.05).
Effects of cyclophosphamide, cis‐platinum, nitrosourea (ACNU), melphalan, and dacarbazine on a cytogenetically highly malignant neuroblastoma xenograft
Authors: Makino Shun‐Ichi , Tsuchida Yoshiaki , Nakajo Toshio , Kanda Naotoshi , Kaneko Yasuhiko 
Published: February 2007

AbstractThe effects of eight different chemotherapeutic agents were studied on a human neuroblastoma xenograft, designated TNB9, according to the standard Battelle Columbus Laboratories protocol. Cytogenetically and molecular‐cytogenetically, this xenograft is known to have a homogeneously staining region (HSR) on chromosome 20 and to exhibit 60‐ to 80‐fold amplification of clone #8 (1.75 kb) and N‐myc (2.1 kb) in the HSR. Our previous analyses of cytogenetic and phenotypic characteristics on nine human neuroblastoma xenografts demonstrated that TNB9 is one of the most malignant strains of neuroblastoma. The in vivo chemotherapeutic sensitivity assessment disclosed that cyclophosphamide, cis‐platinum, nitrosourea (ACNU), melphalan, and dacarbazine (DTIC) are effective, while aclarubicin, vincristine, and cytosine arabino‐side are quite ineffective against this neuroblastoma xenograft.
Statistical evaluation of prognostic factors in ALL and treatment results
Authors: Sather Harland N. 
Published: February 2007

AbstractPrognostic factor evaluation is a frequent and desirable investigative activity in clinical trials. Nevertheless, a number of errors in the evaluation of such factors occur quite commonly. Many of these problems are due to inappropriate statistical interpretation of the analyses that are conducted. A detailed discussion of several problem areas is given. In the area of childhood ALL trials, issues related to the appropriate choice of disease end‐points for analysis of prognostic factors are discussed.
Methotrexate infusions in poor prognosis acute lymphoblastic leukemia: II. High‐dose methotrexate (HDM) in acute lymphoblastic leukemia in childhood: A pilot study from April 1981
Authors: Moe Peter Johan , Wesenberg Finn , Kolmannskog Svein 
Published: February 2007

AbstractThe pilot study using HDM in all cases of ALL in childhood had been run for 41/2 years as of September 1985. Fourteen (23%) of all 62 diagnosed cases of ALL had WBC above 50 × 109/L, all 14 achieved CR. Three of them were below one year of age, two also had WBC above 400 × 109/L, the third infant had B‐cell‐leukemia. The remaining 11 children received our new HDM protocol (Fig. 1), one of them had relapsed (BM) as of September 1985.
Extrarenal rhabdoid sarcoma
Authors: Blatt Julie , Russo Pierre , Taylor Suzanne 
Published: February 2007

AbstractRhabdoid sarcoma is a tumor of unknown etiology that usually occurs in the kidneys of infants and small children. We report an adolescent with a rhabdoid sarcoma of the chest wall, In addition to the patient's age and the site of the tumor, other unusual features of this case were as follows: positive staining of tumor cells with neuron‐specific enolase, the presence of chronic, active, hepatitis that apparently developed coincident with the sar coma, and the presence of widespread hemosiderosis. Two of the patient's siblings died in infancy with degenerative neurologic disease, hepatomegaly, and multiple congenital anomalies. The histochemical findings and family history lend support to previous suggestions that some rhabdoid sarcomas may be of neural crest origin and may be heritable lesions.
Neuro‐ocular damage in pediatric oncology patients: Predictor of long‐term visual disability or tool for limiting toxicity?
Authors: Newman Nancy M. , Donaldson Sarah , De Wit Sharon , King Oscar , Wilbur Jordan R. 
Published: February 2007

AbstractWe present a group of eight pediatric cancer patients with a spectrum of visual afferent pathway abnormalities. Changes include decreased visual acuity, visual field alterations, abnormal visual evoked potentials, changes in the optic disc and nerve fiber layer of the retina, radiation retinopathy, and CNS injury. These changes occur in long term survivors of pediatric malignancy (especially those with prlonged, multimodal, and multicourse therapy), but they may be minimally symptomatic. The changes appear to be analogous to the CNS changes (leukoencephalopathy) described in patients with leukemia and attributed to multimodal therapy.By taking advantage of opportunities to detect adverse effects earlier in the treatment course, the present excellent cure rate may be improved by refinements in therapy that also improve the quality of survival.